Data / New clinical trials / Small Cell Lung Carcinoma

Small Cell Lung Carcinoma trials: 213 new since Nov 2024

Name: New Small Cell Lung Carcinoma clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Small Cell Lung Carcinoma clinical trials: 213 rows for $10.65, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 8 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/small-cell-lung-carcinoma, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 5, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

213 clinical studies in Small Cell Lung Carcinoma were first posted on ClinicalTrials.gov from November 21, 2024 to November 5, 2026; 98 have an industry sponsor and 187 are recruiting or about to. The newest, NCT07920549, was posted on November 5, 2026: A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage... (London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's).

The request: Every new Small Cell Lung Carcinoma clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

213New trials
98Industry sponsored
187Recruiting or not yet
November 5, 2026Latest posted

Newest trials

The newest 100 of 213, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 5, 2026	NCT07920549	A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Phase 2/3	Not yet recruiting	Limited Stage Small-Cell Lung Cancer	150	Canada	clinicaltrials.gov
November 4, 2026	NCT07914764	68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis	Nanjing First Hospital, Nanjing Medical University	Observational	Recruiting	Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma	20	China	clinicaltrials.gov
November 2, 2026	NCT07909863	Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Not yet recruiting	Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage	25	China	clinicaltrials.gov
November 2, 2026	NCT07908667	A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer	Novartis Pharmaceuticals	Phase 1	Not yet recruiting	Extensive-stage Small Cell Lung Cancer	120		clinicaltrials.gov
November 2, 2026	NCT07908537	A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)	Merck Sharp & Dohme LLC	Phase 3	Not yet recruiting	Small Cell Lung Cancer	564		clinicaltrials.gov
October 30, 2026	NCT07905937	Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury	Guizhou Medical University	Observational	Recruiting	Small Cell Lung Cancer ( SCLC ), Brain Injury	42	China	clinicaltrials.gov
October 23, 2026	NCT07892625	A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC	Hansoh BioMedical R&D Company	Phase 1	Not yet recruiting	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	338		clinicaltrials.gov
October 23, 2026	NCT07892300	Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer	Oliver Jonas	Early phase 1	Not yet recruiting	Lung Cancer, Mesothelioma, Suspected Lung Cancer, Suspected Mesothelioma	20		clinicaltrials.gov
October 22, 2026	NCT07890246	A Phase 1 Study of IM-1340 in Participants With Advanced Cancer	Immunome, Inc.	Phase 1	Not yet recruiting	Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm	200		clinicaltrials.gov
October 21, 2026	NCT07886047	Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer	Second Xiangya Hospital of Central South University	Phase 1	Recruiting	Small Cell Lung Cancer (SCLC)	18	China	clinicaltrials.gov
October 21, 2026	NCT07885332	Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer	Ruijin Hospital	Observational	Active not recruiting	Extensive-Stage Small Cell Lung Cancer	26	China	clinicaltrials.gov
October 19, 2026	NCT07881705	A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With...	Jiangsu Simcere Pharmaceutical Co., Ltd.	Phase 3	Active not recruiting	Myelosuppression	106	China	clinicaltrials.gov
October 15, 2026	NCT07874581	Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC	Shanghai Pulmonary Hospital, Shanghai, China	Not applicable	Recruiting	Relapsed Small Cell Lung Cancer (SCLC)	52	China	clinicaltrials.gov
October 7, 2026	NCT07864207	Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)	IDP Discovery Pharma S.L.	Phase 1/2	Recruiting	Small Cell Lung Cancer ( SCLC )	60	Spain	clinicaltrials.gov
September 28, 2026	NCT07843940	A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)	Boehringer Ingelheim	Phase 1/2	Recruiting	Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer	55	Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain...	clinicaltrials.gov
September 15, 2026	NCT07819591	Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC	Shaodong Hong	Phase 2	Not yet recruiting	SCLC, Recurrent	47	China	clinicaltrials.gov
September 4, 2026	NCT07803848	Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor...	AIO-Studien-gGmbH	Phase 2	Recruiting	Small-cell Lung Cancer	57	Germany	clinicaltrials.gov
September 3, 2026	NCT07802821	A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih...	Qilu Pharmaceutical Co., Ltd.	Phase 3	Recruiting	Extensive-stage Small Cell Lung Cancer	556	China	clinicaltrials.gov
September 2, 2026	NCT07798947	A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC	Shanghai Hengrui Pharmaceutical Co., Ltd.	Phase 2	Recruiting	Limited-stage Small-cell Lung Cancer	120	China	clinicaltrials.gov
August 31, 2026	NCT07796100	A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint...	Zai Lab (Shanghai) Co., Ltd.	Phase 3	Not yet recruiting	Extensive-Stage Small Cell Lung Cancer	530		clinicaltrials.gov
August 31, 2026	NCT07795411	Prospective Multiomic Analysis in Small-Cell Lung Cancer	Ohio State University Comprehensive Cancer Center	Observational	Recruiting	Small Cell Cancer Of The Lung, Small Cell Lung Cancer ( SCLC ), Lung Cancer, Small-Cell Lung Cancer (SCLC)	30	United States	clinicaltrials.gov
August 24, 2026	NCT07783477	A Study of Armored CAR T Cells in People With Cancer	Memorial Sloan Kettering Cancer Center	Phase 1	Recruiting	Neuroendocrine Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC )	16	United States	clinicaltrials.gov
August 21, 2026	NCT07778316	Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)	Amgen	Phase 3	Recruiting	Small Cell Lung Cancer	400	Australia, China, Japan, Switzerland, United States	clinicaltrials.gov
August 12, 2026	NCT07759856	NK Cells Plus ICI for SCLC Maintenance	Tianjin First Central Hospital	Phase 2	Recruiting	Small Cell Lung Cancer	42	China	clinicaltrials.gov
August 7, 2026	NCT07752875	A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation	LG Chem	Phase 1/2	Not yet recruiting	Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast...	250		clinicaltrials.gov
August 6, 2026	NCT07749586	A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors	Arvinas Inc.	Phase 1/2	Recruiting	Advanced Solid Tumor	499	United States	clinicaltrials.gov
August 4, 2026	NCT07744698	Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)	Anhui Provincial Cancer Hospital	Phase 4	Recruiting	Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)	107	China	clinicaltrials.gov
August 4, 2026	NCT07744256	Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)	Beijing Biotech	Phase 1/2	Recruiting	Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC	60	China	clinicaltrials.gov
July 28, 2026	NCT07730021	A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors	Astellas Pharma Global Development, Inc.	Phase 1/2	Recruiting	Locally Advanced or Metastatic Solid Tumors	392	Japan, United States	clinicaltrials.gov
July 27, 2026	NCT07728955	A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as...	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 3	Not yet recruiting	Small Cell Lung Cancer ( SCLC )	64		clinicaltrials.gov
July 20, 2026	NCT07713732	TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors	Treeline Biosciences, Inc.	Phase 1	Recruiting	Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas	120	Australia	clinicaltrials.gov
July 16, 2026	NCT07707895	DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine...	Boehringer Ingelheim	Phase 1/2	Not yet recruiting	Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell...	60	Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain...	clinicaltrials.gov
July 1, 2026	NCT07677787	DLL3-Targeted PET/CT in Small Cell Lung Cancer	The First Affiliated Hospital of Xiamen University	Not applicable	Recruiting	PET/CT, Small Cell Lung Cancer ( SCLC ), DLL3-targeted PET/CT, Delta-like Protein 3	20	China	clinicaltrials.gov
June 26, 2026	NCT07670442	Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage...	Assistance Publique - Hôpitaux de Paris	Observational	Not yet recruiting	Small Cell Lung Cancer	50		clinicaltrials.gov
June 17, 2026	NCT07654400	A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer	Biokin (Shanghai) Biopharmaceutical Co., Ltd.	Phase 2	Recruiting	Extensive-stage Small-cell Lung Cancer	36	China	clinicaltrials.gov
June 17, 2026	NCT07652736	A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell...	BeOne Medicines	Observational	Recruiting	Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer	440	Spain	clinicaltrials.gov
June 12, 2026	NCT07646106	THE-0504 in Patients With Solid Tumors	Thena Biotech S.r.l.	Phase 1	Recruiting	Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer...	30	Italy	clinicaltrials.gov
June 11, 2026	NCT07640932	Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer	Yonsei University	Phase 2	Not yet recruiting	Carcinoma, Small Cell Lung	69	South Korea	clinicaltrials.gov
June 9, 2026	NCT07637513	Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer	PrECOG, LLC.	Phase 3	Not yet recruiting	Limited Stage Small-Cell Lung Cancer	430		clinicaltrials.gov
June 9, 2026	NCT07636226	QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer	Sun Yat-sen University	Phase 2/3	Not yet recruiting	Small Cell Lung Cancer	120		clinicaltrials.gov
June 4, 2026	NCT07625644	BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)	SystImmune Inc.	Phase 3	Recruiting	Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung...	550	Australia, Bulgaria, Canada, Czechia, France, Georgia, Germany, Greece...	clinicaltrials.gov
June 3, 2026	NCT07623642	A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or...	GV20 Therapeutics	Phase 2	Not yet recruiting	Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and...	227	China	clinicaltrials.gov
June 3, 2026	NCT07623369	A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors	Huahui Health	Phase 1	Recruiting	Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell...	299	Australia, China	clinicaltrials.gov
May 13, 2026	NCT07583511	Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study	Sun Yat-sen University	Phase 2	Recruiting	Small-cell Lung Cancer	90	China	clinicaltrials.gov
May 4, 2026	NCT07565532	Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment	Shanghai Chest Hospital	Observational	Recruiting	Small Cell Lung Cancer ( SCLC ), Radiotherapy, Immunotherapy, Personalized Cancer Treatment	500	China	clinicaltrials.gov
May 4, 2026	NCT07564401	A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy	Novartis Pharmaceuticals	Phase 1/2	Recruiting	Extensive-stage Small Cell Lung Cancer (ES-SCLC)	80	Australia, Singapore, South Korea, United States	clinicaltrials.gov
April 30, 2026	NCT07559929	A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.	Hangzhou DAC Biotechnology Co., Ltd.	Phase 1/2	Recruiting	Small Cell Lung Cancer	200	China	clinicaltrials.gov
April 30, 2026	NCT07559019	Safety and Preliminary Activity of BI115 in Advanced SCLC	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	Recruiting	Small Cell Lung Cancer (SCLC)	150	China	clinicaltrials.gov
April 29, 2026	NCT07557225	18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors	Peking University First Hospital	Not applicable	Recruiting	Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer, Ovarian Cancer...	200	China	clinicaltrials.gov
April 27, 2026	NCT07551635	SMARCA4/2 Inhibitor for POU2F3-Positive SCLC	Dana-Farber Cancer Institute	Phase 2	Recruiting	Small Cell Lung Cancer	20	United States	clinicaltrials.gov
April 24, 2026	NCT07550842	A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent...	Shanghai Best-Link Bioscience, LLC	Phase 1	Not yet recruiting	Small Cell Carcinoma of Lung	33	China	clinicaltrials.gov
April 24, 2026	NCT07550049	Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology	University of Kansas Medical Center	Observational	Not yet recruiting	Small Cell Lung Cancer, Head and Neck Cancer, Malignant Pleural Mesothelioma	110		clinicaltrials.gov
April 23, 2026	NCT07548788	A Lay Navigation Intervention for Patients With Lung Cancer	University Health Network, Toronto	Not applicable	Not yet recruiting	Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC), Patient Navigation	50	Canada	clinicaltrials.gov
April 23, 2026	NCT07547332	Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2	Not yet recruiting	Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC)	84		clinicaltrials.gov
April 22, 2026	NCT07545954	DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer	Washington University School of Medicine	Phase 1	Recruiting	Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage	20	United States	clinicaltrials.gov
April 20, 2026	NCT07538271	A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer	Yayi He	Phase 2	Not yet recruiting	SCLC, Extensive Stage	33		clinicaltrials.gov
April 20, 2026	NCT07538258	Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer	Yayi He	Phase 2	Not yet recruiting	Limited-stage Small Cell Lung Cancer (LS-SCLC)	27		clinicaltrials.gov
April 17, 2026	NCT07535359	Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer	Daiichi Sankyo	Not applicable	No longer available	SCLC, Extensive-stage Small Cell Lung Cancer	Not listed	United States	clinicaltrials.gov
April 15, 2026	NCT07532057	Pulmonary Rehabilitation During Chemotherapy in Stage IIIB/IV Small Cell Lung Cancer	Istanbul Medipol University Hospital	Not applicable	Completed	Cancer, Lung Neoplasms, Lung Cancer Small Cell Lung Cancer (SCLC)	30	Turkey (Türkiye)	clinicaltrials.gov
April 15, 2026	NCT07531095	Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)	Amgen	Phase 1	Recruiting	Small Cell Lung Cancer	160	Australia, Belgium, France, Germany, Poland, Spain, Switzerland, Turkey...	clinicaltrials.gov
April 14, 2026	NCT07529145	Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment	Medical University of Bialystok	Observational	Recruiting	Non-Small Cell Carcinoma of Lung, Small Cell Carcinoma of Lung	90	Poland	clinicaltrials.gov
April 8, 2026	NCT07517198	Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	Phase 1	Recruiting	Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin...	40	United States	clinicaltrials.gov
April 3, 2026	NCT07510724	Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Observational	Recruiting	Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (Diagnosis)	240	Austria, Germany	clinicaltrials.gov
April 3, 2026	NCT07509333	MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients	West China Hospital	Not applicable	Recruiting	Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma	2,000	China	clinicaltrials.gov
April 3, 2026	NCT07509034	Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or...	National Cancer Institute (NCI)	Phase 1	Recruiting	Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung...	40	United States	clinicaltrials.gov
April 2, 2026	NCT07508852	68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer	Peking University First Hospital	Phase 1/2	Recruiting	SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC )	30	China	clinicaltrials.gov
March 30, 2026	NCT07502300	A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line...	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 3	Recruiting	Extensive-stage Small-cell Lung Cancer	562	China	clinicaltrials.gov
March 30, 2026	NCT07501169	Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	Sichuan University	Phase 2	Not yet recruiting	Extensive-stage Small Cell Lung Cancer (ES-SCLC)	33	China	clinicaltrials.gov
March 24, 2026	NCT07489339	MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy	Shanxi Province Cancer Hospital	Not applicable	Completed	Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Lung Neoplasms	200	China	clinicaltrials.gov
March 23, 2026	NCT07488923	A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC...	Moonlight Bio, Inc	Phase 1	Recruiting	Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC)...	110	United States	clinicaltrials.gov
March 23, 2026	NCT07488676	A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors	Astellas Pharma Global Development, Inc.	Phase 1/2	Recruiting	Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma	150	Japan, United States	clinicaltrials.gov
March 20, 2026	NCT07485920	A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage...	The Affiliated Hospital of Qingdao University	Phase 4	Not yet recruiting	Limited-stage Small Cell Lung Cancer (LS-SCLC)	20	China	clinicaltrials.gov
March 18, 2026	NCT07480213	Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)	Beijing Biotech	Phase 1/2	Recruiting	Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage	60	China	clinicaltrials.gov
March 17, 2026	NCT07476287	Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With...	Pfizer	Phase 2	Recruiting	Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma...	40	Australia, Brazil, China, France, Hong Kong, India, Israel, Italy, Japan...	clinicaltrials.gov
March 16, 2026	NCT07472647	SYS6090 Combination Therapy in Advanced Lung Cancer	Shanghai JMT-Bio Inc.	Phase 1/2	Not yet recruiting	Non-Small Cell Lung Cancer, Small Cell Lung Cancer	596		clinicaltrials.gov
March 16, 2026	NCT07472517	DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and...	Boehringer Ingelheim	Phase 3	Recruiting	Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)	670	Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China...	clinicaltrials.gov
March 12, 2026	NCT07468656	SCLC Tarlatamab Blood Collection	Duke University	Observational	Not yet recruiting	Small-cell Lung Cancer	25		clinicaltrials.gov
March 12, 2026	NCT07465757	A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)	Puma Biotechnology, Inc.	Phase 2	Recruiting	Small Cell Lung Cancer ( SCLC )	50	France, Spain, United States	clinicaltrials.gov
March 10, 2026	NCT07459634	A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC	Jazz Pharmaceuticals	Phase 2	Recruiting	Extensive-stage Small-cell Lung Cancer	50	United States	clinicaltrials.gov
March 6, 2026	NCT07454642	AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors	Avacta Life Sciences Ltd	Phase 1	Recruiting	Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical...	174	United States	clinicaltrials.gov
February 25, 2026	NCT07434518	A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Observational	Recruiting	Small Cell Lung Cancer (SCLC)	500	China	clinicaltrials.gov
February 20, 2026	NCT07424547	Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors	Conjupro Biotherapeutics, Inc.	Phase 1	Recruiting	Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer	386	United States	clinicaltrials.gov
February 20, 2026	NCT07423585	Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer	Asrar Alahmadi	Phase 2	Recruiting	Extensive Stage Lung Small Cell Carcinoma	39	United States	clinicaltrials.gov
February 17, 2026	NCT07414927	A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell...	Shanghai Best-Link Bioscience, LLC	Phase 1/2	Not yet recruiting	Small Cell Carcinoma of Lung	48	China	clinicaltrials.gov
February 12, 2026	NCT07407933	A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors	MediLink Therapeutics (Suzhou) Co., Ltd.	Phase 1/2	Recruiting	Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma	118	Belgium, France, Hungary, Italy, Poland, Romania, Spain, United Kingdom, United...	clinicaltrials.gov
February 11, 2026	NCT07402343	Tarlatamab for SCLC Brain Metastases	Maastricht University Medical Center	Phase 2	Recruiting	Small Cell Lung Cancer, Brain Metastases, Adult	35	Netherlands	clinicaltrials.gov
February 10, 2026	NCT07398560	Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An...	The Third Affiliated Hospital of Harbin Medical University	Phase 2	Not yet recruiting	Small Cell Lung Cancer	47	China	clinicaltrials.gov
February 6, 2026	NCT07391670	A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab	AstraZeneca	Phase 1	Recruiting	Solid Tumours	40	Australia, Georgia, Poland, South Korea, Taiwan	clinicaltrials.gov
February 5, 2026	NCT07390565	YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer	LI FENG	Not applicable	Enrolling by invitation	Extensive-stage Small Cell Lung Cancer (SCLC)	308	China	clinicaltrials.gov
February 5, 2026	NCT07388875	Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC	China Medical University, China	Phase 2	Not yet recruiting	Extensive-Stage Small Cell Lung Cancer	30		clinicaltrials.gov
February 3, 2026	NCT07383454	Lung Cancer Screening in Population Who Had Never Smoked	Chung Shan Medical University	Not applicable	Not yet recruiting	Lung Cancer (Diagnosis), Non-Small Cell Lung Cancer, Small Cell Carcinoma of Lung, Screening Strategy	2,500		clinicaltrials.gov
January 29, 2026	NCT07376499	Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune...	China Medical University, China	Phase 2	Not yet recruiting	Small Cell Lung Cancer	31		clinicaltrials.gov
January 28, 2026	NCT07373964	A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor...	China Medical University, China	Phase 2	Recruiting	Small Cell Lung Cancer	36	China	clinicaltrials.gov
January 26, 2026	NCT07365241	A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants...	AbbVie	Phase 3	Recruiting	Small Cell Lung Cancer	531	Austria, Belgium, Brazil, France, Germany, Greece, Japan, Spain, Switzerland...	clinicaltrials.gov
January 22, 2026	NCT07358676	A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy...	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Recruiting	Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage	25	China	clinicaltrials.gov
January 22, 2026	NCT07357532	Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD	Peking University Cancer Hospital & Institute	Phase 2	Not yet recruiting	Small Cell Lung Carcinoma	44	China	clinicaltrials.gov
January 14, 2026	NCT07339059	Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	Bindu R Potugari	Phase 2	Recruiting	Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)	35	United States	clinicaltrials.gov
January 9, 2026	NCT07328490	Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage...	National Cancer Institute (NCI)	Phase 1/2	Withdrawn	Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma	0	United States	clinicaltrials.gov
January 8, 2026	NCT07325136	A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small...	Bristol-Myers Squibb	Phase 1/2	Recruiting	Relapsed/Refractory Small Cell Lung Cancer	240	China, Italy, Japan, Romania, Spain, United States	clinicaltrials.gov
January 5, 2026	NCT07316309	CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer	Shandong Cancer Hospital and Institute	Observational	Completed	Small Cell Lung Cancer	33	China	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Shanghai Pulmonary Hospital, Shanghai, China	5	October 15, 2026
Amgen	5	August 21, 2026
Peking University Cancer Hospital & Institute	5	January 22, 2026
Novartis Pharmaceuticals	4	November 2, 2026
Sun Yat-sen University	4	June 9, 2026
AstraZeneca	4	February 6, 2026
China Medical University, China	4	February 5, 2026
Tianjin Medical University Cancer Institute and Hospital	3	November 2, 2026
Boehringer Ingelheim	3	September 28, 2026
Qilu Pharmaceutical Co., Ltd.	3	September 3, 2026
Memorial Sloan Kettering Cancer Center	3	August 24, 2026
Shanghai Chest Hospital	3	May 4, 2026
Sichuan University	3	March 30, 2026
AbbVie	3	January 26, 2026
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	3	November 17, 2025
Peking Union Medical College Hospital	3	September 15, 2025
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	2	November 5, 2026
Merck Sharp & Dohme LLC	2	November 2, 2026
Hansoh BioMedical R&D Company	2	October 23, 2026
Zai Lab (Shanghai) Co., Ltd.	2	August 31, 2026

By phase

Phase	New trials	Latest
Phase 2	61	November 2, 2026
Phase 1	37	November 2, 2026
Observational	32	November 4, 2026
Phase 1/2	32	October 7, 2026
Phase 3	24	November 2, 2026
Not applicable	15	October 15, 2026
Phase 2/3	4	November 5, 2026
Early phase 1	4	October 23, 2026
Phase 4	4	August 4, 2026

By country

Country	New trials	Latest
China	108	November 4, 2026
United States	65	September 28, 2026
Spain	27	October 7, 2026
France	21	September 28, 2026
Australia	20	September 28, 2026
Japan	20	September 28, 2026
Italy	19	June 12, 2026
Germany	17	September 28, 2026
South Korea	15	June 11, 2026
Poland	14	September 28, 2026
Turkey (Türkiye)	11	April 15, 2026
Belgium	10	September 28, 2026
United Kingdom	10	July 16, 2026
Canada	9	November 5, 2026
Greece	9	June 4, 2026
Taiwan	9	March 17, 2026
Netherlands	7	September 28, 2026
Switzerland	7	August 21, 2026
Hungary	6	June 4, 2026
Austria	6	April 3, 2026
Brazil	6	March 17, 2026
Israel	6	March 17, 2026
Romania	6	March 16, 2026
Argentina	5	March 16, 2026
Czechia	4	June 4, 2026

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.